GET A VALUABLE CERTIFICATE FOR JOB MARKET


ACADEMIC RECOGNITION OF 3 OR 6 CREDITS


DESIGNED FOR EXPERTS BY EXPERTS


ADVANCED QUANTITATIVE BENEFIT-RISK ASSESSMENT METHODS IN DECISION MAKING ON MEDICINES


Eu2P Certificate: Advanced quantitative benefit-risk assessment methods in decision making on medicines

OBJECTIVES

Decision making on medicines informed by quantitative benefit-risk assessment may differ depending on the perspective of the decision maker and the phase of drug development.

This module will address the decision-making on medicines by different stakeholders and how to apply advanced benefit-risk assessment tools in this process.

Applied decision making, individualized benefit-risk assessment, real life data, graphical representation

 

MODULE PARTS

  1. Multi-criteria decision analysis
  2. Conjoint analysis
  3. Personalized benefit-risk assessment

 

TRAINER TEAM

Coordinator: Dr Shahab Abtahi (from Universiteit Utrecht)

Expert(s): Prof Olaf Klungel, Dr Rianne Van Den Ham, Dr Jet Van Der Zijden, Dr Tjeerd Van Staa, Dr Rob Heerdink, Prof Anke Hilse Maitland - Van Der Zee, Tu Trang (from Universiteit Utrecht), Dr George Quartey (from F. Hoffmann-La Roche Ltd), Dr Filip Mussen (from Janssen Pharmaceutica NV), Dr Hans Hillege, Dr Douwe Postmus (from University Medical Centre Groningen).

Advanced level
75 h workload over 3 months (3 ECTS credits)
Key dates
Course calendar
Certificate award
or included in Master Year 2 or PhD programme
English language
Online based learning
Student : 1,500 €
Professional : 3,000 €
  Savings could be offered under eligibility conditions.

APPLY NOW

Applications open until March 23rd, 2025

Or include this module in your training curriculum choices...

Master Year 2 PhD



Confused? Read the FAQs...

NEED TO TALK TO US?

+33 5 47 30 42 69

Monday-Friday / 9.00am-6.00pm CET

 

Powered By

Eu2P Executive Board partners

Created By

Eu2P project consortium partners